[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-pancreatic-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,45,79,106,129,153,179,202,238,260,289,309,334,357,377,399,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100574136","alpha-radiation-emitters-device-dart-for-the-treatment-of-locally-advanced-pancreatic-cancer-100574136",false,"NCT06755359","Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer","A Safety Study of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Histologically and\u002For cytologically proven locally advanced pancreatic adenocarcinoma\n* Target lesion is technically amenable for Alpha DaRT sources implantation.\n* Measurable lesion per RECIST (version 1.1) criteria\n* Stable disease or tumor response per RECIST (version 1.1) criteria compared to before initiation of mFOLFIRINOX\n* Lesion size ≤ 5 cm in the longest diameter\n* Interstitial radiation indication validated by a multidisciplinary team which includes an oncologist, a radiation oncologist, radiologist, gastroenterologist and a surgeon specialized in pancreatic oncology in the case that a surgical emergency occurs during the procedure\n* Patients have received 8 - 12 cycles of mFOLFIRINOX\n* ECOG Performance Status Scale 0 - 1\n* Life expectancy is more than 6 months\n* WBC ≥ 3500\u002Fµl, granulocyte ≥ 1500\u002Fµl\n* Platelet count ≥60,000\u002Fµl\n* Creatinine ≤1.9 mg\u002FdL\n* AST and ALT ≤ 2.5 X upper limit of normal (ULN)\n* INR \\\u003C 1.4 for patients not on Warfarin\n* Age ≥18 years old\n* Subjects are willing and able to sign an informed consent form\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after initiation of Alpha DaRT therapy\n* Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after DaRT insertion.\n\nExclusion Criteria:\n\n* Concomitant immunotherapy within the past 4 weeks.\n* Patients with metastatic disease\n* Borderline unresectable pancreatic cancer, and\u002For cases fit for surgical exploration unless patient refuses surgery.\n* Known hypersensitivity to any of the components of the treatment.\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.\n* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.\n* Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, low risk prostate cancer, or in situ cervical cancer.\n* Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.\n* Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.","ALL","18 Years","120 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor for the treatment of Locally Advanced Pancreatic Cancer .",[27,28],"Pancreatic Cancer","Locally Advanced Pancreatic Cancer",[30,31],"Alpha radiation","pancreatic cancer","RECRUITING","2026-06-21",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2026-03-01",{"date":40,"type":21},"2027-06",{"name":42,"class":43},"Alpha Tau Medical LTD.","INDUSTRY",12,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100638163","phase-1-study-evaluating-the-safety-feasibility-and-efficacy-of-odi-2001-vaccine-a-personnalized-immunotherapy-in-patients-with-metastatic-or-locally-advanced-colon-cancer-or-pancreatic-cancer-100638163","NCT07587827","Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer","A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer","ODI-2001-01","Inclusion Criteria:\n\n* Patient capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Male or female of \\> 18 years of age\n* Histologically confirmed diagnosis of metastatic or locally advanced solid tumour: • Colorectal carcinoma with MicroSatellite Stable colorectal carcinoma (MSS) not eligible for surgery or other ablative therapies. • Pancreatic adenocarcinoma not eligible for surgery or other ablative therapies.\n* ECOG performance status 0 or 1\n* Baseline Tumoral evaluation (thoraco-abdomino-pelvic computed tomography) performed before the initiation of the standard first line-chemotherapy with at least one measurable lesion according to RECIST 1.1 criteria that can be accurately assessed at baseline and is suitable for repeated assessment.\n* Eligible to start a standard first line chemotherapy indicated in colorectal cancer (FOLFOX\u002FFOLFIRI\u002FFOLFIRINOX or FOLFOXIRI +\u002F- anti-VEGF\u002FEGF) pancreatic cancer (FOLFIRINOX\u002FNabPaclitaxel-Gemcitabine).\n* Adequate haematological, renal and hepatic laboratory requirements : • Haemoglobin \\> 9.0 g\u002FdL • White Blood Cells (WBC) \\> 2.5x109\u002FL including, absolute neutrophils count (ANC) \\> 1.5x109\u002FL, total lymphocytes count \\> 0.5x109\u002FL • Platelet's count \\> 100x109\u002FL• Serum alkaline phosphatase (PAL) ≤ 3 x ULN in the absence of liver or bone metastases and ≤ 5 x ULN in patients with documented bone or liver metastases• Serum transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN in the absence of liver metastases and ≤ 5 x ULN in case of liver metastases\n\n  • Total bilirubin ≤ 1.5 x ULN• Albumin ≥ 30 g\u002FL • Glomerular Filtration Rate ≥ 50 mL\u002Fmin (according to Modification of the Diet in Renal Disease \\[MDRD\\] formula or Cockroft \\& Gault formula)\n* Adequate cardiac function with QTc \\\u003C 450 msec on baseline ECG, using the Fridericia correction cQTcF formula\n* Life expectancy of at least 6 months\n* Patient willing and able to comply with scheduled visits and exams during the follow-up and treatment compliance of the protocol, for the duration of the study including : • mandatory blood sampling (3 blood sampling) • mandatory biopsy of the tumor following enrolment in STEP 1 if no archived material dated less than 2 years is available in sufficient quality or quantity and a mandatory biopsy at 2 months after the initiation of ODI-2001 vaccine administration.\n* Men who are sexually active with women of childbearing potential must agree to use contraceptive method during the ODI-2001 treatment period and for at least 4 months after the last ODI-2001 administration. The individual methods of contraception may be determined in consultation with the investigator and it must have a failure rate of less than 1% per year.\n* A female participant is eligible to participate if she is not pregnant (negative urinary or serum pregnancy test), not breastfeeding, and at least one of the following conditions applies: • Not a woman of childbearing potential OR • Women of childbearing potential who agrees to apply effective contraception method during the treatment period and for at least 4 months after the last dose of study treatment. Effective contraception methods include a combination of any of the following (unless method is abstinence or sterilization, in which only one method is required): - Use of oral, injected, or implanted hormonal methods of contraception, or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C 1%). In case of use of oral contraception, women should have been stable on the same pill for a minimum of 6 months before taking study treatment. - Placement of an intrauterine device or intrauterine system. - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository. - Total abstinence - Female sterilization at least eight weeks before taking study treatment. - Male sterilization (at least six months prior to screening)\n* Patient must be affiliated to a social health insurance regimen\n\nInclusion criteria for ENROLMENT STEP 1 :\n\nFirst tumoral evaluation shows disease response with the following definition:\n\n* Colorectal carcinoma: A decrease of at least 30% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = at least partial response definition according to RECIST 1.1 definition.\n* Pancreatic carcinoma: A decrease of at least 20% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = adaptative RECIST 1.1 definition.\n\n  * Availability of tumoral material in sufficient quality and quantity in FFPE to performed dB209 manufacturing (5-10 slides according to tissue surface area) + tumoral microenvironment assessment (10 slides). In case of lack of tumoral material to performed the mandatory 2 analysis, a new biopsy should be organized.\n\nInclusion criteria for ENROLMENT STEP 2\n\n* Second tumoral evaluation shows disease response with the following definition:\n\n  * Colorectal carcinoma: A decrease of at least 30% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = at least partial response definition according to RECIST 1.1 definition.\n  * Pancreatic carcinoma: A decrease of at least 20% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = adaptative RECIST 1.1 definition.\n* Patient eligible for a 6-week chemotherapy break, with the start of maintenance treatment beginning in week 7.\n\nExclusion Criteria:\n\n* Patients with \\>10% hepatic involvement as per investigator\n* Exposure to any investigational agent within 30 days of enrolment.\n* Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n* History of any second malignancy within 2 years with the exception of malignancies with a negligible risk of metastasis or death (e.g. adequately treated carcinoma-in situ of the breast or the cervix, melanoma-in-situ, prostate cancer with Gleason grade ≤6 and prostate specific antigen within normal range).\n* Known or suspected history of immunosuppression (severe auto-immune or immunodeficiency disease) including history of invasive opportunistic infections (e.g tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis, aspergillosis) despite infection resolution. Presence or suspicion of active bacterial, fungal or viral infections, or uncontrolled fever\n* Patients with major surgery within 4 weeks from enrolment\n* Previous vaccination (either therapeutic and\u002For prophylactic) against cancer\n* Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, ototoxicity, vitiligo, and the laboratory values defined in the inclusion criteria.\n* Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) unless used at dose levels that are not immunosuppressive (e.g. Prednisone at 10 mg\u002Fday or less or as inhaled steroid at doses used for the treatment of asthma) up to 14 days before pre-enrolment.\n* Is receiving growth factors including, but not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, etc. within 4 weeks from enrolment\n* Known history of Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence of HBs antigen in the serum\n* History of severe auto-immune or immunodeficiency disease\n* Known allergy to any of the components of ODI-2001 (e.g. egg or gentamycin)\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty\n* Planned to receive yellow fever or other live (attenuated) vaccines during the course of the study\n* Recent or active clinically significant infection requiring therapy at the time of first dose\n* Any persistent or unresolved drug-related toxicity following previous treatment\n* Myocardial infarction or stroke within previous 6 months, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure\n* Known symptomatic malignant brain lesion\n* Patients with any serious uncontrolled disease or psychiatric condition that, in the opinion of the Investigator, might interfere with the patient's participation in the trial or interfere with the interpretation of trial results",{"count":54,"type":21},77,[56],"PHASE1","This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab), in patients with metastatic or locally advanced colorectal or pancreatic cancer. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) followed by an expansion phase to evaluate efficacy in terms of progression-free survival",[59,60,61,28],"Metastatic Colorectal Cancer (CRC)","Locally Advanced Colorectal Cancer","Metastatic Pancreatic Cancer",[63,64,65,66],"vaccine","pancreas","colorectal","phase 1","NOT_YET_RECRUITING","2026-05-11",{"date":70,"type":36},"2026-05-14",{"date":72,"type":21},"2026-11-01",{"date":74,"type":21},"2031-05-01",{"name":76,"class":77},"Centre Georges Francois Leclerc","OTHER",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":78},"100335823","phase-1-phase-i-nab-paclitaxel-plus-gemcitabine-with-proton-therapy-for-locally-advanced-pancreatic-cancer-lapc-100335823","NCT03652428","Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)","Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Cytologic or histologic proof of adenocarcinoma of the pancreas.\n2. Nonmetastatic pancreatic cancer. Metastatic disease includes spread to distant (non-regional) lymph nodes, organs, peritoneum and ascites.\n3. Unequivocal radiographic findings contraindicating resection including, but not limited to, solid tumor contact with any of the following: 1) the SMA \\>180º; 2) the celiac axis \\>180º; 3) the first jejunal superior mesenteric artery (SMA) branch; 4) unreconstructible superior mesenteric vein (SMV)\u002Fportal vein due to tumor involvement or occclusion; 5) the most proximal draining jejunal branch into the SMV.\n4. ECOG Performance Status 0 or 1.\n5. Absolute neutrophil count ≥1,000\u002Fmm3\n6. Platelet count ≥100,000\u002Fmm3\n7. Creatinine ≤1.5 × upper limit of normal\n8. Calculated creatinine clearance \\>45 mL\u002Fmin\n9. Total bilirubin ≤2 mg\u002FdL\n\nExclusion Criteria:\n\n1. Patients with resectable or borderline resectable pancreatic cancer are ineligible.\n2. No prior definitive resection of pancreatic cancer.\n3. No prior radiation therapy to the abdomen that would overlap fields required in this study. Prior radiotherapy for other disease is allowed.\n4. No prior chemotherapy except for FOLFIRINOX, Gem-Abrax, or Gem-Cap. A patient may be registered for the trial while undergoing chemotherapy.\n5. Any grade 4 toxicity prior to start of chemoradiotherapy that may be due to induction chemotherapy.\n6. Greater than 2 dose reductions during induction chemotherapy.\n7. Chronic concomitant treatment with strong inhibitors of CYP3A4. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to the start of study treatment. Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment.\n8. Baseline Grade ≥ 2 neuropathy. Known Gilbert's disease or known homozygosity for UGAT1A1\\*28 polymorphism.\n9. Pregnant and\u002For breastfeeding. Patient must have a negative pregnancy test within 14 days of study entry if they are in childbearing years\u002Fpremenopausal.\n10. Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with gemcitabine and nab-paclitaxel.\n11. Non-compliance with induction chemotherapy.","75 Years",{"count":88,"type":21},24,[56,90],"PHASE2","The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy on each Monday of those three weeks.",[28],[94,95,96],"LAPC","Nab-paclitaxel +Gemcitabine","Proton Therapy","2026-05-05",{"date":99,"type":36},"2026-05-06",{"date":101,"type":36},"2019-04-02",{"date":103,"type":21},"2026-12-31",{"name":105,"class":77},"University of Maryland, Baltimore",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100625977","phase-2-endoscopic-ultrasound-guided-loco-regional-chemotherapy-injection-as-adjuvant-therapy-for-locally-advanced-pancreatic-cancer-100625977","NCT07429643","Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age \\> 18 years old.\n* Patients recently diagnosed to have pancreatic adenocarcinoma based on histopathological examination.\n* Locally advanced potentially resectable pancreatic cancer . .Eastern Cooperative Oncology Group performance status of 0 to 1. .Signed informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old.\n* Metastatic pancreatic cancer.\n* prior pancreatic surgery or chemotherapy or radiotherapy. concurrent or prior malignancy. coexistent medical condition precluding protocol therapy.","60 Years",{"count":115,"type":21},20,[90,117],"PHASE3","this is a randomized controlled trial aims to compare between patients with locally advanced pancreatic cancer treated with EUS-guided injection of gemcitabine in addition to systemic chemotherapy, versus those who treated with the standard systemic chemotherapy alone, regarding to(progression -free survival and response rate).\n\nResearchers will compare Arm A: patients received EUS-FNI of gemcitabine plus standard systemic chemotherapy to Arm B : patients receiving the standard systemic chemotherapy alone.",[28],"2026-02-20",{"date":122,"type":36},"2026-02-24",{"date":124,"type":21},"2026-04-15",{"date":126,"type":21},"2028-12-30",{"name":128,"class":77},"Assiut University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":152},"100624253","combined-chemotherapy-and-ablative-radiotherapy-sbrt-as-first-line-treatment-in-locally-advanced-inoperable-pancreatic-cancer-sbrt-panc-100624253","NCT07407231","Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)","Efficacy Of Combination Chemotherapy And Ablative Radiotherapy (SBRT) In The First-Line Treatment Of Locally Advanced Inoperable Pancreatic Cancer","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Locally advanced, inoperable pancreatic cancer\n* Treated with first-line systemic chemotherapy followed by stereotactic body radiotherapy (SBRT) at participating centers\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Metastatic pancreatic cancer\n* Prior systemic therapy for locally advanced pancreatic cancer (one or more previous lines of systemic treatment)\n* Disease progression after initial chemotherapy prior to SBRT\n* Any condition that, in the investigator's opinion, would interfere with study participation or evaluation",{"count":137,"type":21},18,[24],"This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally advanced, inoperable pancreatic cancer.\n\nThe study aims to determine the response rate after SBRT delivered following initial chemotherapy, as well as time to disease progression and treatment-related toxicity. Patients receive standard first-line chemotherapy and, in the absence of disease progression, undergo ablative SBRT to the primary tumor, followed by continuation of systemic therapy according to clinical practice.\n\nThe study is conducted in Slovenia, with patient enrollment expanded to additional participating clinical centers following an approved amendment.",[28],[142,143],"SBRT","Stereotactic Body Radiotherapy","2026-02-12",{"date":146,"type":36},"2026-02-17",{"date":148,"type":36},"2021-09-01",{"date":103,"type":21},{"name":151,"class":77},"Institute of Oncology Ljubljana",1,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":178},"100617945","chemotherapy-with-or-without-imd10-focused-ultrasound-in-the-treatment-of-borderline-resectable-or-locally-advanced-pancreatic-cancer-100617945","NCT07325214","Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer","A Randomized Pivotal Clinical Trial Evaluating Chemotherapy Regimen Consisting of Irinotecan Hydrochloride, Oxaliplatin, Fluorouracil (5-FU) and Leucovorin With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable Pancreatic Cancer or Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* An individual must meet all the following criteria:\n* 1\\. Willing and able to understand and sign an ICF and to comply with all aspects of the protocol\n* 2\\. Aged between 18 and 85 years, inclusive\n* 3\\. Histologically or cytologically, pathologically confirmed diagnosis of PDAC.\n* 4\\. Classification as BRPC or LAPC according to the NCCN Guidelines (The latest Edition) by radiologic test (CT or MRI), eligible for chemotherapy regimen within 4 weeks of the screening visit\n* 5\\. Must have at least 1 measurable lesion per RECIST 1.1 criteria at the screening visit.\n* 6\\. The ECOG performance status 0 or 1\n* 7\\. Trial participant having laboratory values defined as: Neutrophil count ≥ 1.5 x 10\\^9\u002FL, Platelet count ≥ 100 x 10\\^9\u002FL, AST and ALT ≤ 2.5 x ULN, - Serum creatinine ≤ 1.5 x ULN\n* 8\\. Life expectancy is more than 12 weeks\n* 9\\. A female is eligible to trial participate if not pregnant, not breast feeding and either a woman not of childbearing potential or, if a woman of childbearing potential agrees to use highly effective methods of contraception\\* from screening to EOS\n* 10\\. A male trial participant with female partner(s) of childbearing potential agrees to use highly effective methods of contraception from screening to EOS\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participating in this clinical trial:\n* 1\\. The presence of a cystic lesion within tumor to be treated, or at the pancreas adjacent to the treated tumor.\n* 2\\. Extensive scars or surgical clips observed in the region through which the ultrasound beam will pass\n* 3\\. Targeted tumor(s) is not clearly visible with IMD10.\n* 4\\. Tumor is not treatable by the working range of IMD10\n* 5\\. Patient has difficulty in lying in supine position\n* 6\\. Known history of severe hypersensitivity to ultrasound gel or to chemotherapies (irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin) used in this clinical trial\n* 7\\. Known history of another anti-tumor therapy including chemotherapy, radiation, and\u002For surgery for pancreatic cancer\n* 8\\. A cardiovascular condition at the time of the screening visit that deems trial participation inappropriate due to one or more of the following: ① Class III or IV heart failure according to New York Heart Association (NYHA) classification, ② Acute coronary syndrome (unstable angina or myocardial infarction) within the last 24 weeks, ③ Uncontrolled heart arrhythmia, ④ Other clinically significant cardiovascular abnormalities as determined by the investigator\n* 9\\. Known history at the time of the screening visit that deems trial participation inappropriate due to one or more of the following: ① Other uncontrolled chronic infectious diseases, ② Active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing spondylitis, etc.), ③ Congenital or acquired immunodeficiency diseases, such as cellular immunodeficiency, hypogammaglobulinemia, and hypergammaglobulinemia., ④ Clinically significant mental illness\n* 10\\. Known history of malignancies other than pancreatic cancer within the last 2 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ (e.g., breast, cervix)\n* 11\\. Known history of major surgery within 4 weeks of the cycle 1 day 1 (C1D1)\n* 12\\. Pregnant and breastfeeding women\n* 13\\. Trial participating in another drug\u002Fdevice clinical trial or have participated in another drug\u002Fdevice clinical trial within 4 weeks of C1D1\n* 14\\. Trial participation in the clinical trial is deemed inappropriate at the investigator's discretion, either for ethical reasons or due to potential impact on the clinical trial's outcome","85 Years",{"count":162,"type":21},136,[24],"The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.",[27,166,28],"Borderline Resectable Pancreatic Cancer",[168],"Focused Ultrasound","2026-01-08",{"date":171,"type":36},"2026-01-12",{"date":173,"type":21},"2026-04",{"date":175,"type":21},"2029-08",{"name":177,"class":43},"IMGT Co., Ltd.",5,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100305501","phase-3-intra-arterial-gemcitabine-vs-iv-gemcitabine-and-nab-paclitaxel-following-radiotherapy-for-lapc-100305501","NCT03257033","Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer","TIGeR-PaC","Inclusion Criteria:\n\n1. Histologically or Cytopathology confirmed pancreatic adenocarcinoma with initial diagnosis within 8 weeks of consent for patients who enroll at cycle 1, and from the start of cycle 1 of gemcitabine + nab-paclitaxel chemotherapy for patients who enroll at cycle 2\n2. Locally advanced, unresectable disease at screening and prior to randomization, as defined by NCCN criteria determined by an on-site, experienced, multidisciplinary team (as confirmed by CT or MRI within 30 days of the start of cycle 1)\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1\n4. Age ≥ 18 years\n5. Adequate laboratory values prior to receiving the first dose of nab-paclitaxel and gemcitabine: (criterion must be met prior to cycle 2.) For a subject with elevated bilirubin, AST or ALT, who has had a biliary stent placed, if the subject's lab values have returned to within the required range for eligibility noted below in sub-criteria e and f \\[(AST) ALT ≤ 3.0 X the upper normal limit, and total bilirubin ≤ 1.5 X the upper normal limit\\] after placement of stent and prior to cycle 2, he\u002Fshe is eligible for the study. Additional details regarding eligibility for subjects who have had biliary stents recently placed are outlined in sub-criteria f and h below.\n\n   1. Absolute neutrophil count (ANC) ≥ 1,500\u002FμL\n   2. Platelet count ≥ 100,000\u002FμL\n   3. Hemoglobin ≥ 9.0 g\u002FdL\n   4. Serum creatinine ≤ 1.5 mg\u002FdL OR creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2 for subjects with creatinine \\>1.5 mg\u002FdL\n   5. \\*Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 X the upper normal limit of institution's normal range\n   6. \\*Total bilirubin ≤ 1.5 X the upper normal limit of institution's normal range -OR- If biliary stent is placed or planned to be placed within 6 weeks of Cycle 1 Day 1 (C1D1), total bilirubin ≤ 2.0 X the upper normal limit of institution's normal range (see section 9.1.4 for dose modification due to elevated bilirubin)\n   7. Prothrombin time (PT) and partial thromboplastin time (PTT) must be ≤ 1.5 X upper normal limit of institution's normal range. Subjects who are currently taking anti-coagulant therapy are eligible if not meeting this criterion\n   8. International normalized ration (INR) ≤ 1.5 X upper normal limit of institution's normal range. Subjects who are currently taking anti-coagulant therapy are eligible if not meeting this criterion \\*For elevated AST, ALT, and total bilirubin at screening, subject must have a normalized result prior to initiation of Cycle 2 if abnormal labs are considered related to bile duct obstruction and a biliary stent has been placed\n6. Life expectancy \\> 12 weeks\n7. Negative pregnancy test for women of childbearing potential (either serum or urine) within one day prior to administration of the first dose of chemotherapy. Women of childbearing potential should use highly effective methods of contraception during treatment and for up to 6 months following treatment cessation\n8. Provide written informed consent\n9. Subjects willing to participate in the study for at least 8 months if randomized to IA gemcitabine OR IV gemcitabine + nab-paclitaxel\n\nExclusion Criteria:\n\n1. Any prior treatment for pancreatic cancer OR more than one cycle of gemcitabine and nab-paclitaxel treatment. For subjects who have started on their first cycle of gemcitabine and nab-paclitaxel treatment prior to consent, Inclusion Criterion #1 only applies to the first gemcitabine and nab-paclitaxel dose and must be within 6 weeks of confirmed diagnosis\n2. Any evidence of metastatic disease or another active malignancy within the past one year except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.\n3. Subjects unable or unwilling to have their first randomized treatment within 3 weeks of the post induction imaging and within 5 weeks of their last induction treatment\n4. Subjects without baseline tumor imaging\n5. As determined by the Sponsor:\n\n   Arterial anatomy unsuitable for IA delivery of gemcitabine to the intended tumor site, determined by CT or MRI, as determined and approved by the Sponsor Imaging Advisor, which includes the following:\n   1. Stenosis or occlusion in the intended artery for treatment\n   2. Inability to exclude major side branches in the area of the intended RenovoCath® catheter occlusion\n   3. No suitable artery with a diameter greater than 3 mm in proximity of at least one side of the tumor\n   4. Superior mesenteric vein (SMV) occlusion or stenosis that cannot be resolved with medication or intervention prior to randomization, if the superior mesenteric artery (SMA) is the only viable treatment artery Note: Arterial Anatomy will be reviewed by the Sponsor, RenovoRx Imaging Advisor, and RenovoRx Medical Monitor for approval\n6. Contraindications for SBRT planning which includes the following:\n\n   1. Gastrointestinal mucosal infiltration evident at the time of diagnostic endoscopy\n   2. Prior abdominal radiotherapy judged to have clinically significant degree of overlap with planned SBRT dose distribution Note: Primary tumors with a diameter greater than 7 cm must be assessed on a case-by-case basis with the RenovoRx Imaging Advisor prior to excluding the subject from the trial.\n7. Subjects with known HIV infection or active viral hepatitis\n8. Severe infections requiring hospitalization within 4 weeks prior to the first study treatment, including but not limited to complications of infection, bacteremia or severe pneumonia\n9. Signs or symptoms of infection within 2 weeks prior to the first study treatment, as assessed by the Investigator\n10. Received antibiotics for treatment of an infection within 48 hours prior to initiation of study treatment. Subjects receiving prophylactic antibiotics are eligible\n11. History of severe allergic, anaphylactic, or other hypersensitivity reactions to gemcitabine or nab-paclitaxel\n12. Any anti-cancer therapy including chemotherapy, hormonal therapy for prostate cancer, or radiotherapy within 2 weeks prior to initiation of study treatment; or herbal therapy intended as anti-cancer therapy within 1 week prior to initiation of study treatment\n13. Subjects with uncontrolled seizures\n14. Cardiovascular disease including unstable angina or life-threatening cardiac arrhythmia, myocardial infarction, stroke; or New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) within the last 3 months prior to the first study treatment. Subjects with prior history of Myocardial Infarction (MI), congestive heart failure (CHF), coronary artery bypass grafting, or prior valve surgery need to have assessment of ejection fraction (EF) to ensure EF is not ≤ 40% (as determined by MRI, ECHO, or Nuclear Scan), within the last 3 months prior to the initiation of study treatment\n15. Other severe concurrent disease or comorbidities which make it difficult to participate in this study, as assessed by Investigator\n16. Any of the following procedures prior to initiation of study treatment:\n\n    1. Catheterization, endoscopy, stent or drain placement within 48 hours. (Diagnostic laparoscopy without surgical intervention and\u002For port placement do not require any wait time prior to study treatment)\n    2. Minor surgery requiring light sedation (such as surgical laparoscopy) within 2 weeks\n    3. Major surgery within 4 weeks\n17. Women who are breastfeeding\n18. Male or female subjects of reproductive potential who do not agree to either remain abstinent or employ highly effective and acceptable forms of contraception throughout their participation in the study and for 6 months after the last study treatment\n19. Subjects receiving any other investigational agents within 2 weeks prior to the initiation of treatment\n20. Any social situations or psychiatric illness that would limit compliance with study requirements\n21. Subjects unable or unwilling to have standard catheterization procedure",{"count":188,"type":21},190,[117],"The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.",[28],"2025-11-13",{"date":194,"type":36},"2025-11-14",{"date":196,"type":36},"2018-03-12",{"date":198,"type":21},"2026-09",{"name":200,"class":43},"RenovoRx",42,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":152},"100514215","microenvironment-tumor-effects-of-radiotherapy---comprehensive-radiobiology-assessment-trial-100514215","NCT05975593","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)","METEOR-CRATR","Inclusion Criteria:\n\n* Confirmation of intent to receive radiotherapy for one of the following diagnoses:\n\n  * Cervical cancer\n  * Pancreatic cancer\n* ECOG performance status ≤ 2\n* At least 18 years old\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nExclusion Criteria:\n\n* Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician",{"count":211,"type":21},60,[24],"This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.",[215,216,217,218,28,219,220,27,221,222],"Locally Advanced Cervical Carcinoma","Locally Advanced Cervical Cancer","Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Carcinoma","Cervical Cancer","Pancreas Cancer","Cancer of the Cervix","Cancer of the Pancreas",[224,225,226,227,228],"Radiotherapy","Chemotherapy","Cervical cancer","Pancreatic cancer","Biospecimen","2025-11-07",{"date":231,"type":36},"2025-11-12",{"date":233,"type":36},"2024-01-11",{"date":235,"type":21},"2032-12-31",{"name":237,"class":77},"Washington University School of Medicine",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":78},"100383761","systemic-therapy-with-a-loco-regional-treatment-in-patients-with-locally-advanced-pancreatic-cancer-100383761","NCT04276857","Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer","Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study","SMART","Inclusion Criteria:\n\nAdult patients with biopsy-proven locally advanced pancreatic adenocarcinoma who are candidates for combination chemotherapy as determined by treating oncologists.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Metastatic pancreatic cancer\n3. Another active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.",{"count":247,"type":21},27,[24],"Background\n\nPancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for curative surgery. The optimal management of patients with locally advanced pancreatic cancer remains unknown. Most patients are treated with chemotherapy alone and role of local treatment such as radiation is not well defined. Other conventional ablative therapies such as thermal ablation and cryoablation have limited role in locally advanced pancreatic cancer due to the risk of collateral damage to the adjacent structures. Irreversible electroporation (IRE) is a novel non-thermal ablation technology that does not cause injury to nearby blood vessels, ducts, and bowel and has potential to provide longer disease control and thereby a better overall survival. The current study aims to prospectively validate effectiveness and safety of IRE in real-world patients with locally advanced pancreatic cancer.\n\nObjectives\n\n1\\) To determine 12-month progression-free survival (PFS) and 24-month overall survival rates of patients with locally advanced pancreatic cancer who are treated with combination chemotherapy and IRE and 2) to compare progression-free and overall survival of patients with locally advanced pancreatic cancer who are treated with combination chemotherapy and IRE versus combination chemotherapy alone.\n\nDesign\n\nProspective multicenter single arm study.\n\nMethods\n\nBased on the assumption of doubling of PFS of patients who are being treated with IRE and chemotherapy versus chemotherapy alone we estimated a sample of n=27 of adult patients with histologically proven non-metastatic locally advanced adenocarcinomas. Eligible patients will be recruited at the two major cancer centers in Saskatchewan. All IRE eligible patients will receive 12 weeks of induction chemotherapy and will undergo repeat imaging studies. If there is no disease progression IRE will be performed. An additional 12 weeks of chemotherapy will be recommended. Patients who are not eligible for IRE due to size criteria will receive chemotherapy at the discretion of treating oncologist till disease progression or till they become eligible for IRE. Quality of life will be assessed every three months or until disease progression.\n\nSignificance\n\nDespite progress in the management of most solid organ cancers and better outcomes, little advancement has been made in the treatment of patients with locally advanced pancreatic cancer. Unfortunately, most patients have very limited life expectancy. There is an unmet need for novel approaches in the management of patients with locally advanced pancreatic cancer. IRE in combination with chemotherapy has potential to improve local disease control and thereby improves survival and may prove a valuable tool to add in the multidisciplinary treatment of cancer. The result of this study will be used for the development of a future multicenter national phase III trials.",[28,251],"Irreversible Electroporation","2025-05-07",{"date":254,"type":36},"2025-05-13",{"date":256,"type":36},"2025-05-01",{"date":103,"type":21},{"name":259,"class":77},"University of Saskatchewan",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":270,"phases":4,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":178},"100588683","a-new-clinical-pathway-for-personalized-management-of-borderline-resectable-and-locally-advanced-pancreatic-cancer-100588683","NCT06944587","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)","NORPACT-3","Inclusion Criteria:\n\n* Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)\n* Nx, M0 (UICC 8th version, 2016)\n* Cytological or histological confirmation of adenocarcinoma\n* Age \\>18 year\n* Considered able to receive primary chemotherapy and possible surgery\n* Written informed consent\n\nExclusion Criteria:\n\n* Co-morbidity or performance status precluding primary chemotherapy\n* Co-morbidity or performance status precluding pancreatectomy\n* Female patients in child-bearing age not using adequate contraception, pregnant or lactating women\n* Mental or physical disorders that could interfere with treatment of with the provision of informed consent\n* Any reason why, in the opinion of the investigator, the patient should not participate",{"count":269,"type":21},400,"OBSERVATIONAL","NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity\u002Fmortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival \\>20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).",[28,166,273,274],"Pancreatectomy","Chemotherapy Effect",[276,277,166,28,273,274,278,279],"Primary chemotherapy","Resection rate","FDG PET-CT","ctDNA","2025-04-17",{"date":282,"type":36},"2025-04-25",{"date":284,"type":36},"2024-12-03",{"date":286,"type":21},"2028-12-31",{"name":288,"class":77},"Oslo University Hospital",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":178},"100489464","phase-3-clinical-study-of-tumor-treating-fields-combined-with-gemcitabine-and-albumin-bound-paclitaxel-in-the-first-line-treatment-of-locally-advanced-pancreatic-cancer-100489464","NCT05653453","Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Subjects aged between 18 and 75 (including 18 and 75) of both genders;\n2. Expected survival time ≥3 months;\n3. Pancreatic adenocarcinoma confirmed by histology\u002Fcytology;\n4. Locally advanced lesions meeting any of the following criteria without distant metastasis: ① Pancreatic head and neck tumors: a. The tumor invaded the Superior Mesenteric Artery (SMA) more than 180°; b. The tumor invaded the celiac trunk more than 180°; c. Unresectable reconstruction of superior mesenteric vein or portal vein due to tumor invasion or embolism (tumor thrombus or thrombus); d. The tumor extensively invaded the distal jejunal drainage branch of the superior mesenteric vein. ② Pancreatic body\u002Ftail tumor: a. The tumor invaded the superior mesenteric artery or celiac trunk more than 180°; b. Celiac trunk and abdominal aorta involvement; c. The superior mesenteric vein or portal vein cannot be resected and reconstructed due to tumor invasion or embolism (tumor thrombus or thrombus).\n5. At least one measurable lesion according to revised RECIST version 1.1;\n6. ECOG score 0-1;\n7. Be able to receive gemcitabine for injection and paclitaxel for injection (albumin-bound) combined therapy according to medical advice;\n8. Able to operate tumor treating fields independently or with the help of nursing staff;\n9. AE should be restored to normal or CTCAE1 grade after previous treatment;\n10. The serum pregnancy test results of female subjects of reproductive age were negative. Female subjects of reproductive age agree to use effective contraception (e.g. hormonal or barrier methods or abstinence) during the study period and for 6 months after the last dose of chemotherapy drugs;\n11. Male subjects agree to use effective birth control (such as barrier method or abstinence) and not to donate sperm during the study and within 3 months after the last chemotherapy drug administration;\n12. Voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. The subjects has previously received first-line treatment for pancreatic adenocarcinoma;\n2. Subjects with contraindications to treatment with gemcitabine for injection and\u002For paclitaxel for injection (albumin-bound) or known severe allergies to gemcitabine for injection and\u002For paclitaxel for injection (albumin-bound);\n3. Patients had cancer requiring other antitumor therapy within 2 years before enrollment, excluding treated stage I prostate cancer, cervical cancer in situ, breast cancer in situ, and non-melanoma skin cancer;\n4. Abnormal bone marrow, heart, liver and kidney function: a. Neutrophil count \\\u003C 1.5 × 10\\^9\u002FL, platelet count \\\u003C 100 × 10\\^9\u002FL, hemoglobin \\\u003C 90g\u002FL; The use of blood transfusion, platelet transfusion and erythropoietin was prohibited within 14 days before C1D1, and the use of Leukocytotropic drug such as G-CSF, fegrasstim, pefegrasstim, etc., was prohibited within 7 days before C1D1.b. Total bilirubin \\> 1.5× Upper Limit of Normal (ULN); Subjects with a total bilirubin \\> 2×ULN that is elevated due to pancreatic cancer compression of the bile duct but has been fitted with a bile duct stent for drainage can be enrolled. AST and\u002For ALT\\> 2.5×ULN; the use of drugs that improve liver function, such as reducing transaminase was prohibited within 7 days before C1D1. c. Serum creatinine \\> 1.5×ULN; d. A history of severe cardiovascular disease, including but not limited to second or third degree heart block; Severe ischemic heart disease; New York Heart Association (NYHA) class II or higher congestive heart failure (mild physical activity limitation; Comfortable at rest, but normal activities can cause fatigue, palpitations, or difficulty breathing);\n5. Subjects who were required to receive systemic corticosteroids (doses equivalent to \\> 10 mg prednisone\u002Fday) or other immunosuppressive agents within 14 days before enrollment or during the study period. Subjects were eligible for enrollment if: a. The use of topical or inhaled glucocorticoids is permitted; b. Allow short-term (≤7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases;\n6. Those who had severe infection before the first dose were judged ineligible for the study by the investigator;\n7. History of human immunodeficiency virus (HIV) infection (known HIV1\u002F2 antibody positive);\n8. The presence of active hepatitis B, active hepatitis C, or other active infections that may affect the patient's treatment as determined by the investigator;\n9. Subjects with a clear history of neurological or psychiatric disorders, such as epilepsy, dementia, or substance abuse (including alcohol) within the last year, and possibly affecting compliance;\n10. Infected, ulcerated or unhealed wounds exist on the skin where the tumor treating fields is applied;\n11. Having an implantable electronic medical device, such as a pacemaker;\n12. Metal medical instruments are implanted in the chest and abdomen such as bone nails;\n13. Known allergies to medical adhesives or hydrogels;\n14. Pregnant or breastfeeding;\n15. Subjects participated in clinical trials of other drugs within 3 months before enrollment, or participated in clinical trials of other devices within 1 month before enrollment;\n16. Subjects with poor compliance or other factors as judged by the investigator.",{"count":296,"type":21},512,[117],"The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.",[28],"2025-03-20",{"date":302,"type":36},"2025-03-24",{"date":304,"type":36},"2022-12-20",{"date":306,"type":21},"2027-09-28",{"name":308,"class":43},"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100574572","phase-1-mfolfirinox-plus-anlotinib-and-sintilimab-for-advanced-pancreatic-cancer-100574572","NCT06761027","mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","mFOLFIRINOX Combined With Anlotinib and Sintilimab as First-Line Therapy for Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-arm, Multicenter, Phase Ib\u002FII Clinical Study","Inclusion Criteria:\n\n1. Fully understand this study and voluntarily sign the informed consent form;\n2. Age between 18 and 75 years inclusive, with no gender restrictions;\n3. Patients with locally advanced or metastatic pancreatic cancer diagnosed by histology or cytology;\n4. No prior anti-cancer treatment;\n5. Patients must have at least one measurable lesion (according to RECIST 1.1 criteria);\n6. ECOG PS score of 0-1;\n7. Expected survival of at least 3 months;\n8. No severe organic diseases of the heart, lungs, brain, liver, kidneys, or other organs;\n9. Women of childbearing age must agree to use contraceptive measures during the treatment period and for 6 months after the end of treatment; negative serum or urine pregnancy test within 7 days before study enrollment, and must be non-lactating, men must agree to use contraceptive measures during the study period and for 6 months after the study ends.\n\nExclusion Criteria:\n\n1. Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment;\n2. Known allergies to any of the drugs in the study;\n3. Symptomatic brain metastases or metastases with symptom control time less than 2 months;\n4. A large liver metastasis burden, occupying more than 70% of the liver volume;\n5. Patients with obstructive jaundice whose bilirubin cannot be reduced to the expected level after adequate decompression;\n6. Presence of any active autoimmune diseases or patients with autoimmune diseases expected to relapse (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes);\n7. History of immunodeficiency; patients currently using immunosuppressants, systemic corticosteroid therapy, or any other form of immunosuppressive treatment;\n8. Known genetic or acquired bleeding tendencies (such as coagulation disorders) or thrombosis, such as hemophiliacs; currently using or have recently (within 10 days before the start of the study treatment) used full-dose oral or injectable anticoagulants or thrombolytic drugs for therapeutic purposes (preventive use of low-dose aspirin, low molecular weight heparin is allowed);\n9. Serious infections (CTC AE greater than grade 2) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, infectious complications, etc.; baseline chest imaging suggests active pulmonary inflammation, presence of symptoms and signs of infection within 2 weeks before the first use of the study drug, or requiring oral or intravenous antibiotic treatment (excluding the use of antibiotics for prevention);\n10. History of other malignant tumors within the past 5 years or concurrently, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid carcinoma;\n11. Patients with mental illness; history of abuse of psychotropic drugs, alcoholism, and drug addiction;\n12. Pregnant or lactating women;\n13. Deemed by the investigator as unsuitable to participate in this trial for other reasons.",{"count":317,"type":21},29,[56,90],"This study is a prospective, single-arm, multicenter, phase Ib\u002FII clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.",[28,61],[322,323],"anlotinib","sintilimab","2025-01-04",{"date":326,"type":36},"2025-01-07",{"date":328,"type":36},"2024-12-23",{"date":330,"type":21},"2027-05",{"name":332,"class":77},"Fujian Provincial Hospital",4,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100567506","phase-2-nalirifox-combined-with-pd-1-sequential-radiotherapy-versus-nalirifox-as-conversion-therapy-of-locally-advanced-pancreatic-cancer-100567506","NCT06669078","NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","A Prospective, Open, Randomized Controlled, Multicenter, Exploratory Clinical Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer","NALIRIFOX","Inclusion Criteria:\n\n1. Histologically or cytologically confi rmed pancreatic cancer;\n2. ECOG performance no more than 1;\n3. Radiographically assessed as locally advanced pancreatic cancer according ;\n4. No previous anti-tumor therapy;\n5. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. Prior anti-tumor therapy of any kind;\n2. Known to be symptomatic central nervous system metastasis and\u002For cancerous meningitis.\n3. Patients with autoimmune disease or immune deficiency who are treated with immuno-suppressive drugs;\n4. Patients with bleeding tendency;\n5. Pregnant or lactating women.",{"count":343,"type":21},120,[90],"The purpose of the prospective, open, randomized controlled, multicenter, exploratory clinical study is to evaluate efficacy and safety of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer",[28],[340,348,28],"Conversion Therapy","2024-10-30",{"date":351,"type":36},"2024-11-01",{"date":349,"type":21},{"date":354,"type":21},"2027-10-15",{"name":356,"class":77},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":78},"100554086","nalirifox-combined-with-pd-1-sequential-radiotherapy-versus-ag-combined-with-pd-1-sequential-radiotherapy-as-first-line-treatment-of-locally-advanced-pancreatic-cancer-100554086","NCT06494514","NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer","A Single-center, Randomized, Interventional Controlled Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy for First-line Treatment of Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed pancreatic cancer;\n2. ECOG performance no more than 2;\n3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;\n4. No previous anti-tumor therapy；\n5. Able and willing to provide a written informed consent;\n\nExclusion Criteria:\n\n* 1\\. Prior anti-tumor therapy of any kind; 2. Severe infection (\\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.",{"count":20,"type":21},[24],"The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.",[28],"2024-07-02",{"date":370,"type":36},"2024-07-10",{"date":372,"type":36},"2024-04-01",{"date":374,"type":21},"2027-04-01",{"name":376,"class":77},"Du Juan",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":152},"100515197","phase-2-surufatinib-and-serplulimab-combined-with-ag-regimen-compare-with-ag-regimen-as-conversion-therapy-for-patients-with-locally-advanced-pancreatic-cancer-sage-100515197","NCT05988372","Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : a Phase II Randomized Controlled PILOT Study (SAGE)","Inclusion Criteria:\n\n1. Written informed consent obtained from the patient prior to treatment.\n2. Pathologically confirmed unresectable locally advanced pancreatic cancer, received no surgical therapy.\n3. Age between 18 and 75 years at the time of study entry.\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n5. Measurable or evaluable lesions according to RECIST v1.1 criteria.\n6. Life expectancy ≥ 12 weeks.\n7. There are no serious organic diseases of the heart, lungs, brain and other organs.\n8. Adequate functioning of the bone marrow and major organs function meeting the following criteria:\n\n   1. White blood cell count ≥ 4 × 109\u002FL, Neutrophil count ≥ 1.5 × 109\u002FL, Platelets count ≥ 100 × 109\u002FL,Hemoglobin ≥ 90 g\u002FL.\n   2. Normal coagulation function, without active bleeding or thrombotic diseases: INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN.\n   3. Liver function: Total serum bilirubin ≤ 1.5 ×ULN, Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 3 × ULN, Obstructive Jaundice with total serum bilirub ≤ 1.5 x ULN after internal\u002F external drainage.\n   4. Kidney function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL\u002Fmin.\n   5. Cardiac function:left ventricular ejection fraction (LVEF) of 50%≥ on 2D cardiac ultrasound.\n9. Male or female patients of potential for childbearing who voluntarily used effective contraceptive methods such as double-barrier contraception, condoms, oral or injection avoidance or pregnancy medications, IUDs, etc during the study period and within 6 months of the last study medication . All female patients will be considered fertile unless the female patient is naturally menopausal.\n\nExclusion Criteria:\n\n1. Participants diagnosed pancreatic cancer with distant metastases.\n2. Participation in other antineoplastic drug clinical trials within 4 weeks prior to enrollment;\n3. Previous systemic antitumor therapy (chemotherapy, radiation, targeted or immunoth, etc.).\n4. Diagnosis of any second malignancy, except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix uteri.\n5. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n6. Active or prior documented autoimmune or inflammatory disorders.\n7. Participants are being treated with immunosuppressants, or systemic or absorbable topical hormones for immunosuppressive purposes (dose\\> 10 mg\u002Fday prednisone or other equivalent hormones) , and the use is still continued within 2 weeks before enrollment.\n8. Have undergone any surgery (other than biopsy) or invasive treatment or manipulation within 4 weeks prior to enrollment and the surgical incision has not healed completely (except intravenous catheterization, puncture drainage, internal or external drainage of obstructive jaundice, etc.)\n9. Participants with abnormal thyroid function who were unable to maintain thyroid function within the normal range with medical treatment.\n10. Hypertension that cannot be controlled in the presence of optimal treatment is defined as systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg.\n11. Urinary routine showed that urinary protein ≥2+, and 24-hour urinary protein\\>1.0g.\n12. Participantst currently has any disease or condition that affects the absorption of the drug, or the participants cannot take sulfatinib orally\n13. participants with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding\\>30 mL within 3 months with hematemesis, melena, hematochezia), hemoptysis (fresh blood\\>5 mL within 4 weeks); Patients with history of hereditary or acquired bleeding or coagulation dysfunction, with clinically significant bleeding symptoms or definite bleeding tendency within 3 months, such as gastrointestinal bleeding and hemorrhagic gastric ulcer.\n14. Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe\u002Funstable angina, or coronary bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) grade \\> 2 for congestive heart failure; ventricular arrhythmias requiring drug therapy; Electrocardiogram (ECG) showing QT interval ≥480 ms;\n15. Severe infection that is active or uncontrolled:\n\n    1. Inherited or acquired immunodeficiency disease,\n    2. Known clinically significant history of liver disease, including viral hepatitis \\[known hepatitis B virus (HBV) carriers must exclude active HBV infection , HBV DNA positive (\\>1×104 copies\u002FmL or \\>2000 IU\u002Fml)\\];\n    3. known hepatitis C virus infection (HCV) and positive HCV RNA (\\>1×103 copies\u002Fml) or other hepatitis, cirrhosis.\n16. Pregnant or lactating women or participants with family planning during the trial period.\n17. Participants have a known history of psychotropic substance abuse, alcoholism, or drug abuse.\n18. The investigator believes that the participant has any clinical or laboratory abnormalities or other reasons that are unsuitable for this clinical study.",{"count":385,"type":21},50,[90],"This is a Phase II Randomized Controlled PILOT clinical study. The purpose of this study is to explore the efficacy and safety of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine in the conversion therapy for patients with unresectable locally advanced pancreatic cancer. Furthermore, it compares the efficacy of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine to the albumin-paclitaxel and gemcitabine regimen in the conversion therapy for patients with unresectable locally advanced pancreatic cancer.",[28],[28,348],"2023-10-30",{"date":392,"type":36},"2023-11-01",{"date":394,"type":21},"2023-10-23",{"date":396,"type":21},"2026-10-23",{"name":398,"class":77},"Sun Yat-sen University",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100516784","phase-2-sbrt-combined-with-zimberelimab-gls-010-in-locally-advanced-pancreatic-cancer-spark-1-study-100516784","NCT06009029","SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","A Multicenter, Single-arm, Prospective Study of SBRT Combined With Zimberelimab (GLS-010) in Patients With Locally Advanced Pancreatic Cancer (SPARK-1 Study)","Inclusion Criteria:\n\n* 18-75 years old.\n* Locally advanced pancreatic cancer confirmed histologically and defined according to the NCCN Pancreatic Cancer Guidelines v1.2022 as unresectable or surgically declined.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* The expected survival ≥ 3 months.\n* At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.\n* Patient must have adequate organ function defined by the study-specified laboratory tests.\n\nExclusion Criteria:\n\n* Tumor invasion of the gastrointestinal tract, specifically pancreatic tumor or lymph node metastasis invading the gastrointestinal parenchyma.\n* Woman who are pregnant or breastfeeding.\n* Has a known additional malignancy within the past 5 years, except for cured skin cancer and cervical carcinoma in situ.\n* Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.\n* Contraindications to immunotherapy.\n* Other conditions that investigator decides not suitable for the trial.",{"count":407,"type":21},96,[90],"This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).",[28],[28,142,412],"Zimberelimab","2023-08-22",{"date":415,"type":36},"2023-08-24",{"date":417,"type":21},"2023-08",{"date":419,"type":21},"2027-07",{"name":421,"class":77},"Peking University Third Hospital",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":429,"enrollmentInfo":4,"targetDuration":4,"studyType":430,"phases":4,"briefSummary":431,"conditions":432,"keywords":436,"overallStatus":441,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":445,"locationsCount":152},"100192898","magnetic-resonance-guided-high-intensity-focused-ultrasound-treatment-of-locally-advanced-pancreatic-cancer-100192898","NCT01786850","Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer","Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer: Phase II Study for Pain Palliation and Local Tumor Control","Inclusion Criteria:\n\n* biopsy proven unresectable pancreatic adenocarcinoma;\n* unable or not willing to undergo chemo-radiation therapy\n* Celiac plexus alcoholization failed to control pain symptoms\n\nExclusion Criteria:\n\n* contraindication to MR or general anesthesia","90 Years","EXPANDED_ACCESS","Patients with unresectable pancreatic cancer in most of cases cannot benefit from percutaneous ablation modalities, due to high risk of procedure-related complications. Ultrasound-guided high intensity focused ultrasound (HIFU) ablation has been introduced as a feasible treatment option in these patients. However, in other anatomical regions US-guided HIFU has been replaced by the more accurate MR-guided focused ultrasound (MRgFUS) ablation, but the applicability of this latter technique to the treatment of pancreatic cancer is still unexplored. The aim of this study is to explore feasibility and clinical performance of MRgFUS ablation of unresectable pancreatic cancer. Two are the main end-points: Pain palliation and local tumor control.\n\nAs compared to conventional US-guided HIFU, MRgFUS could represent a more accurate, non-invasive ablation modality even for unresectable pancreatic cancer although, to date, no cases of pancreatic MRgFUS ablation have been reported.",[433,434,28,435],"Pancreas","Cancer","Non-invasive Treatment",[437,438,439,440],"Locally advanced Pancreatic Cancer","Noninvasive treatment","High Intensity focused ultrasound","Magnetic Resonance","AVAILABLE","2014-06-17",{"date":444,"type":21},"2014-06-18",{"name":446,"class":77},"University of Roma La Sapienza"]